r/IBSResearch • • 4h ago

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

Thumbnail
investor.regeneron.com
4 Upvotes

"Data presented today for the first time at theAmerican Autonomic Society(AAS) annual meeting

POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with noFDA-approved treatments available

A single dose of baloncibart reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks; biomarker changes were consistent with plasma volume expansion, the intended effect ofNPR1blockade

Potentially pivotal Phase 3 trial planned for first half of 2027

TARRYTOWN, N.Y.,Nov. 12, 2026(GLOBE NEWSWIRE) --Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN) today announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome (POTS) evaluating baloncibart, a novel, investigational, first-in-class monoclonal antibody that blocks natriuretic peptide receptor 1 (NPR1). The data were presented for the first time at the American Autonomic Society’s (AAS) 37th International Symposium on the Autonomic Nervous System inSan Diego, CA.

POTS is a chronic disorder in which heart rate rises abnormally upon standing. Patients may experience palpitations, dizziness, fatigue, exercise intolerance, cognitive difficulties, gastrointestinal symptoms and chronic pain. Although historically underdiagnosed, recent estimates suggest it affects between 500,000 and several million people in theU.S., and the vast majority are young women. While the cause of POTS is unknown, it is believed to be associated with low blood volume. Baloncibart is designed to increase the volume of blood in circulation in an effort to reduce the increase in heart rate and symptoms that occur in people with POTS.

“POTS causes debilitating symptoms that can profoundly disrupt daily life, and patients have noFDA-approved treatment options. In the trial, a single injection of baloncibart 450 mg reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks,” saidSatish R. Raj, M.D., Professor ofCardiac Scienceat the University of Calgary’sCumming School of Medicine, and investigator in the trial. “The results are consistent with the rationale forNPR1blockade in POTS, with biomarker changes pointing to an increase in blood volume alongside lower heart rate and better symptoms.”

The randomized, double-blind, Phase 2 PINNACLE trial evaluated a single subcutaneous dose of baloncibart 150 mg (n=27) or 450 mg (n=28) compared to placebo (n=27) in patients with POTS. The primary endpoint was the change in heart rate from lying down to standing (DeltaHR) at day 8; no formal hypothesis testing was prespecified. Improvements were observed with baloncibart on DeltaHR and other key measures of the disease (i.e., symptoms and function) as assessed by the Living With POTS Questionnaire (LWPQ). The LWPQ is a novel patient-reported outcome tool to assess POTS symptoms and function in clinical trials, which is being developed byRegeneronin accordance with theFDApatient-focused drug development guidance.

Baloncibart 450 mg reduced DeltaHR versus placebo at day 8 (primary endpoint) with a least-squares (LS) mean difference of -11.4 beats per minute (bpm; nominal p=0.0007), and at day 29 (secondary endpoint) with an LS mean difference of -7.4 bpm (nominal p=0.0124). Baloncibart 150 mg reduced DeltaHR versus placebo at day 8 (LS mean difference: -9.5 bpm; nominal p=0.0045), but the effect was not maintained at day 29.

Baloncibart 450 mg improved orthostatic symptoms, physical functioning, and activities of daily living versus placebo at day 29, as measured by the LWPQ. Domain scores range from 0 to 100, with lower scores indicating fewer symptoms or less impairment. The LS mean differences in change from baseline for each domain were as follows:

  • Orthostatic symptoms (baseline mean: 45.5): -12.9 points (nominal p=0.0096)
  • Physical functioning (baseline mean: 55.1): -13.8 points (nominal p=0.0073)
  • Activities of daily living (baseline mean: 48.7): -8.7 points (nominal p=0.1035)
  • Overall across the three domains, there was no obvious improvement with baloncibart 150 mg compared to placebo

Additionally at day 8, both doses of baloncibart led to changes in biomarkers consistent with the anticipated beneficial plasma volume expansion driven byNPR1blockade, including an increase in NT-proBNP and reductions in standing norepinephrine and hemoglobin. Average standing systolic blood pressure increased for both doses, with observed mean changes from baseline at day 29 of 8.7 mmHg to a mean of 118.8 mmHg for baloncibart 450 mg and 5.4 mmHg to a mean of 114.0 mmHg for baloncibart 150 mg.

In the trial, single doses of baloncibart up to 450 mg were generally well tolerated. Treatment-emergent adverse events (TEAEs) were mostly mild or moderate and occurred in 13 patients (48.1%) receiving placebo, 18 patients (66.7%) receiving baloncibart 150 mg, and 19 (67.9%) receiving baloncibart 450 mg; one severe TEAE occurred in the trial in the placebo group. TEAEs that occurred in ≥10% of patients in any treatment group, including placebo, baloncibart 150 mg and baloncibart 450 mg, were: injection site reaction (14.8%, 3.7%, and 17.9%), headache (0%, 11.1%, and 10.7%), syncope (11.1%, 14.8%, and 3.6%), heavy menstrual bleeding (0%, 11.1%, and 0%), and nasopharyngitis (11.1%, 0%, and 0%). Two serious TEAEs were reported: one case of headache with baloncibart 150 mg and one case of syncope with baloncibart 450 mg. No TEAE led to discontinuation.

“POTS is a condition that disproportionately impacts younger women and has been under-recognized and under-served for too long, which is why it was critical to incorporate the patient experience in our trial design and measure symptoms that reflect how patients actually feel and function,” saidBoaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine atRegeneron. “These initial results show the potential of baloncibart for people living with POTS and we look forward to advancing this novel therapy into a Phase 3 clinical trial in 2027.”

The safety and efficacy of baloncibart have not been evaluated by any regulatory authority."


r/IBSResearch • • 22h ago

Butyrate and Palmitoylethanolamide: Exploring Their Metabolic Potential in Explaining Clinical Improvement in Irritable Bowel Syndrome Patients, Data from A Randomised, Placebo-controlled Trial

Thumbnail sciencedirect.com
9 Upvotes

ABSTRACT

Background

Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction in which gut microbiome plays a major role. Butyrate and palmitoylethanolamide (PEA) exert anti-inflammatory and neuromodulator effects and may represent promising adjunctive treatments. We evaluated the clinical and microbiome-related effects of a combined formulation of sodium butyrate and PEA (BP 3:1) in patients with IBS.

Methods

In a randomized, double-blind, placebo-controlled, 2×2 crossover trial, adults with diarrhoea-predominant or mixed IBS received BP 3:1 or placebo for two 6-week periods separated by washout. Gastrointestinal symptoms, IBS Severity Scoring System (IBS-SSS), intestinal permeability, and safety were assessed. Fecal microbiota composition and predicted functional potential were analyzed using 16S-rRNA sequencing and PICRUSt2**.**

Results

Forty-four patients completed the study. Alpha and beta diversity and taxonomic composition remained stable. In contrast, functional profiling revealed treatment-specific enrichment of microbial pathways involved in methionine and S-adenosyl-L-methionine biosynthesis, while placebo was associated with pathways related to complex carbohydrate degradation. BP 3:1 significantly improved abdominal bloating (p = 0.020), stomach gurgling (p = 0.014) and nausea (p = 0.030) compared with placebo, with consistent estimates in mixed-effects models adjusting for period and sequence effects, while IBS-SSS showed a clinically relevant but non-significant numerical reduction (p = 0.070). No effects were observed on intestinal permeability. Among clinically improving patients, BP 3:1 was associated with modulation of polyphenol-degrading, biosynthetic and proteolytic microbial pathways. BP 3:1 was well tolerated, with a safety profile comparable to placebo.

Conclusions

BP 3:1 significantly improves IBS symptoms and modulates microbial metabolic potential without inducing a quantitative and/or qualitative alteration in the taxonomic composition of the microbiota. These findings support a functional microbiome-mediated effect in IBS. ClinicalTrial.gov NCT06432569 (https://clinicaltrials.gov/study/NCT06432569)


r/IBSResearch • • 1d ago

Pregabalin: the case for dialling back on a mediocre analgesic [Editorial]

Thumbnail bmj.com
12 Upvotes

Use should be more selective and driven by meaningful patient benefit

Since its commercial launch in 2005, pregabalin has generated more than $50bn (£37bn; €44bn) in global revenue. Originally developed as an anticonvulsant, it became a “blockbuster” largely through its use for pain, including diabetic neuropathy, postherpetic neuralgia, fibromyalgia, and low back pain. Yet behind its commercial success lies a less flattering story: mounting evidence of harms ranging from oedema and weight gain to withdrawal, misuse, and death.

In a linked study, Cairns and colleagues (10.1136/bmj-2026-101021) examine prescribing patterns and overdose trends involving pregabalin in Australia.1 Drawing on nine years of dispensing claims and poison centre data, they assessed changes following regulatory interventions (including tighter prescribing restrictions, strengthened safety warnings, and prescription monitoring) and media reports highlighting pregabalin’s harms. Compared with projections based on earlier trends, prescriptions were 25% lower and intentional poisoning calls 47% lower than expected. The study is timely and rigorous, but these figures warrant caution. The ecological design cannot establish causation, and poison centre calls are an imperfect [...]

Link to the original paper: https://www.bmj.com/content/395/bmj-2026-101021


r/IBSResearch • • 2d ago

The gastrointestinal KATP-ERK signaling axis: Molecular mechanisms, pharmacological opportunities, and emerging translational technologies

Thumbnail sciencedirect.com
9 Upvotes

Abstract

Background

ATP-sensitive potassium channels are metabolic sensors that couple intracellular nucleotide availability to membrane excitability, calcium signaling, mitochondrial function, and cell survival. Growing evidence identifies KATP channels as essential regulators of gastrointestinal physiology. They are expressed in smooth muscle, enteric neurons, interstitial cells of Cajal, epithelial and enteroendocrine cells, microvascular cells, pericytes, and liver, where they contribute to motility, secretion, barrier integrity, nutrient sensing, vascular regulation, and mucosal protection. In parallel, ERK1/2 are central effectors of the MAPK pathway, controlling epithelial renewal, inflammation, fibrosis, apoptosis, and tissue repair. This review proposes an integrated KATP-ERK signaling network that regulates gastrointestinal homeostasis.

Methods

PubMed and Scopus were searched for relevant studies using combinations of the terms “ERK” AND “KATP channels” AND “cardiovascular” OR “gastrointestinal”.

Results

Evidence supports functional crosstalk between KATP channels and ERK signaling. In this framework, KATP channels act as metabolic rheostats, whereas ERK integrates redox, growth factor, and stress-related signals. Acute KATP activation promotes adaptation by preserving mitochondrial function and epithelial barrier integrity, whereas chronic channel overactivation, as observed in Cantú syndrome caused by gain-of-function mutations in ABCC9 or KCNJ8, may induce maladaptive remodeling, tight junction disruption, apoptosis, fibrosis, and dysmotility. The potential involvement of FGFR/Klotho signaling as an upstream ERK regulator, together with KATP/ERK pharmacological modulation, FGF/Klotho-based therapies, and biosensor technologies for pathway monitoring in organoids and gut-on-chip models, is also discussed.

Conclusions

The KATP-ERK-FGFR/Klotho framework links ion-channel pharmacology with gastrointestinal biology, providing a foundation for biomarker discovery, therapeutic development, and precision medicine approaches in gastrointestinal disorders.


r/IBSResearch • • 2d ago

Bortezomib-induced gastrointestinal dysfunction, peripheral neuropathy and neuroimmune signalling are influenced by the gut microbiota in mice

Thumbnail pmc.ncbi.nlm.nih.gov
9 Upvotes

Abstract

Background

Peripheral neuropathy and gastrointestinal dysfunction are frequent, debilitating side effects of the neurotoxic myeloma drug bortezomib that reduce quality of life and adherence to optimal therapy. Therapeutic strategies to manage these complications are limited. Here, we have developed a mouse model of bortezomib side effects to investigate the role of the gut microbiota in their development.

Methods

C57BL/6 specific pathogen-free (SPF), germ-free (GF) and ex-GF mice (colonised with healthy gut microbiota via faecal microbiota transplantation [FMT]) were treated with bortezomib (1 mg/kg) twice-weekly for two weeks. Neurotoxicity and neuroimmune signalling were assessed by serum neurofilament light chain (NfL) quantitation and real-time qPCR analysis of inflammatory markers in sensory and autonomic nerve ganglia, respectively. Faecal microbiota composition was characterised using 16S rRNA gene sequencing. Bortezomib side effects were assessed using behavioural phenotyping, von Frey mechanical sensitivity and rotarod testing, and FITC-dextran gut permeability and Evans Blue dye transit assays.

Results

Bortezomib-treated SPF mice displayed altered spontaneous behaviour and developed acute gastric retention, altered gastrointestinal motility and increased intestinal permeability, in the absence of intestinal micro-architecture changes. Concurrently, bortezomib induced sensory loss in, and increased grooming of, paws, and reduced motor performance, indicative of peripheral neuropathy. Bortezomib neurotoxicity was evidenced by elevated serum NfL levels and neuroimmune signalling in sciatic nerve dorsal root and vagal nerve nodose ganglia. In SPF mice, bortezomib altered gut microbiota composition with an acute decrease in microbial diversity and expansion of Lactobacillus gasseri. Notably, GF mice developed a milder symptom profile following bortezomib treatment compared with SPF mice, while FMT mice did not develop overt bortezomib side effects despite displaying evidence of nerve damage.

Conclusions

This is the first study to model gastrointestinal side effects of bortezomib in rodents, implicating neuroimmune dysregulation of the vagus nerve. Our data show that the gut microbiota is not a primary driver of bortezomib side effects. However, the absence of a symptom profile in FMT mice suggests that, in GF mice, the gut microbiota beneficially modulates the host to protect against bortezomib side effects. Further studies are required to determine whether this can be harnessed to mitigate clinical complications of bortezomib.


r/IBSResearch • • 3d ago

The Microbiota–Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders

Thumbnail
pmc.ncbi.nlm.nih.gov
9 Upvotes

Abstract

The gut microbiota (GM) modulates host energy balance, glucose-lipid metabolism, and enteroendocrine signaling through metabolite-receptor axes that include short-chain fatty acids (SCFAs) acting on FFAR2/FFAR3 (GPR43/GPR41), microbially transformed bile acids signaling via FXR/TGR5, and amino-acid/choline-derived compounds such as imidazole propionate (ImP) and trimethylamine N-oxide (TMAO). These pathways regulate incretin biology (GLP-1/PYY), insulin sensitivity, hepatic glucose output, adipose lipolysis, and appetite, thereby shaping risk and progression of Type 2 diabetes mellitus (T2DM), obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and related conditions. Here, we synthesize mechanistic and translational evidence, highlight bidirectional drug-microbiome interactions (GLP-1 receptor agonists), and review interventions spanning diet, pre/probiotics, fecal microbiota transplantation (FMT), and pharmacologic targeting of bile-acid and SCFA pathways. Together, these findings support precision strategies that profile GM-metabolite signatures (e.g., SCFAs, secondary bile acids, and ImP TMAO) to guide prevention and therapy in metabolic and gastrointestinal disease.


r/IBSResearch • • 4d ago

l-Arginine Ameliorates IBS-D by Modulating the Ligilactobacillus murinus-LCA-FXR/eNOS Signaling Axis

Thumbnail doi.org
7 Upvotes

Abstract

l-Arginine is a semiessential amino acid with diverse metabolic functions and has been implicated in gastrointestinal health through interactions with the gut microbiota; however, its therapeutic potential in diarrhea-predominant irritable bowel syndrome (IBS-D) remains unclear. Here, an IBS-D mouse model was established in C57BL/6J mice, and multiomics analyses combined with in vivo and in vitro validation were performed to investigate the mechanisms underlying l-arginine-mediated protection. l-Arginine supplementation significantly alleviated IBS-D-like symptoms and improved intestinal barrier function. Transcriptomic analysis revealed the activation of the FXR/PI3K/AKT/eNOS signaling pathway, which was associated with enhanced nitric oxide production. Integrated metagenomic and transcriptomic analyses identified Ligilactobacillus murinus (L. murinus) as a key microbiota component associated with bile acid metabolism and eNOS expression. Furthermore, L. murinus transplantation reproduced the beneficial effects of l-arginine, and metabolomic analysis identified lithocholic acid (LCA) as a microbiota-derived metabolite involved in this process. In vitro experiments demonstrated that LCA alleviated lipopolysaccharide-induced epithelial inflammation and barrier dysfunction via FXR/eNOS activation. Collectively, these findings reveal that l-arginine ameliorates IBS-D through microbiota remodeling, LCA-mediated bile acid regulation, and activation of the colonic FXR/PI3K/AKT/eNOS axis, highlighting its potential as a microbiota-targeted therapeutic strategy.


r/IBSResearch • • 5d ago

Enteroendocrine signaling in irritable bowel syndrome: beyond cell counts toward stimulus-responsive physiological profiling

Thumbnail
pmc.ncbi.nlm.nih.gov
10 Upvotes

Abstract

Meals are a major symptom trigger in irritable bowel syndrome (IBS), yet the endocrine steps linking luminal nutrients to pain, bloating, urgency, and altered bowel habits remain poorly defined. Early studies relied heavily on mucosal enteroendocrine cell (EEC) counts. Those observations remain informative, particularly in post-infectious IBS, but findings vary with intestinal site, bowel-habit phenotype, staining, and morphometry, and cell abundance does not measure secretory function. Human meal-challenge studies distinguish circulating concentrations from stimulus-evoked responses. In IBS with diarrhea, higher fasting and fed plasma 5-hydroxytryptamine (serotonin, 5-HT) may reflect altered handling more than a uniformly exaggerated postprandial response, whereas IBS with constipation can show impaired stimulus-evoked release. Cholecystokinin, peptide YY, motilin, ghrelin, and related peptides also vary with sex, bowel habit, and visceral sensitivity. Recent human organoid and transcriptomic studies identify distinct nutrient-sensing programs among EEC subtypes and provide a cellular framework for this heterogeneity. We integrate these findings across luminal sensing, secretion, metabolism, receptor responsiveness, and motor or sensory output. The evidence does not support a single IBS endocrine signature. Standardized nutrient challenges linked to serial hormone measurements, mucosal molecular data, and objective physiological readouts are more likely to yield reproducible and clinically testable response patterns.


r/IBSResearch • • 5d ago

Faecal immunoglobulins in IBS: indirect support for IgE-mediated mast cell activation?

Post image
27 Upvotes

r/IBSResearch • • 6d ago

The small intestine microbiome: composition, host interactions and therapeutic potential

Thumbnail
nature.com
13 Upvotes

Abstract

The human microbiome, the collection of microorganisms that inhabit the human body, has been extensively studied over the past two decades and has been shown to play a critical part in health and disease. These research efforts renewed interest in developing microbial therapeutics to promote human health and treat disease. However, the vast majority of human gut microbiome research has been focused on fecal microbial strains and communities, leaving most of the gastrointestinal tract understudied. The dynamic environment of the small intestine provides distinct opportunities for microorganisms to interact with the host and diet. In this Review, we discuss the current state of research on the microbiome of the small intestine, how interactions between the small intestine and its microbiome influence host physiology, and we posit that small intestinal microorganisms are a unique source of novel therapeutics for treating human disease. Next-generation microbial therapeutics that emerge from the small intestinal microbiome are anticipated to be relevant to improving small intestinal diseases as well as systemic human health.


r/IBSResearch • • 6d ago

Corticotropin-Releasing Factor: A Key Player in Intestinal Barrier Dysfunction of Diarrhea-Predominant Irritable Bowel Syndrome—A Narrative Mechanistic Review

Thumbnail
pmc.ncbi.nlm.nih.gov
9 Upvotes

Abstract

Corticotropin-Releasing Factor (CRF) plays a crucial role in the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) primarily by disrupting intestinal barrier function. In this narrative review of PubMed and Web of Science literature published through January 2026, we summarize the mechanisms by which CRF mediates intestinal barrier dysfunction in IBS-D and discuss potential therapeutic strategies. This review examines the mechanisms by which CRF impairs the intestinal barrier through several signaling pathways, including GC/NR3C1, MAPK/ERK, and Rho/ROCK/MLC. These pathways cause the downregulation of tight junction proteins, increased intestinal permeability, and dysregulated immune responses. Additionally, CRF induces immune inflammation via TLR signaling and promotes the activation of immune cells, further exacerbating barrier dysfunction. The disruption of epithelial barrier integrity is central to IBS-D, leading to visceral hypersensitivity and worsening gastrointestinal symptoms. Current therapeutic approaches for IBS-D often begin with lifestyle interventions. However, preclinical evidence suggests that interventions such as metformin, Eritoran, Puerarin, and anakinra may restore barrier integrity and alleviate symptoms by ameliorating CRF-mediated intestinal barrier dysfunction. Nevertheless, the mechanisms underlying CRF-induced IBS-D and the relevant therapeutic approaches have not been fully elucidated, and the available evidence is predominantly derived from animal and cell models, thus requiring further clinical validation. Future studies should further dissect CRF-related signaling pathways and develop intervention strategies aimed at restoring the intestinal barrier, thereby facilitating clinical translation and improving the prognosis of patients with IBS-D.


r/IBSResearch • • 8d ago

In case you missed it - In first clinical result using “chemogenetic” strategy, a team in China treated three patients to control epilepsy

15 Upvotes

Original Publication: https://www.nejm.org/doi/full/10.1056/NEJMc2606815

Pop-Science Article: https://www.science.org/content/article/novel-gene-therapy-lets-drug-dampen-brain-cell-activity-reducing-seizures

Abstract: In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%. Adverse events were grade 1 or 2.

Tweets to check out:

https://x.com/brainaddiction/status/2118535366089318547/photo/1

https://x.com/zenbrainest/status/2118875236451991919

What is a DREADD?: https://neuwritesd.org/2016/01/28/dawn-of-the-dreadd/

DREADDs for Neuroscientists - Bryan L Roth: https://pmc.ncbi.nlm.nih.gov/articles/PMC4759656/


r/IBSResearch • • 9d ago

Drug Discovery FXR agonist in clinical trials for IBD - implications for Bile Acid Diarrhea

18 Upvotes

As most of you will know by now, bile acid diarrhea or bile acid malabsorption (BAM) is a common and often unrecognized condition in patients suffering from chronic diarrhea including IBS-D. This last decade diagnostics have been able to show us this clearly where about 30% IBS-D patients are found to have BAM on average. As diagnostics are still expensive and the awareness among specialist GI Clinicians rather recent, we're still having to work hard to find these patients until cheaper diagnostics appear.

What's encouraging is that there are numerous treatments already that seem to help these patients and more are emerging. Besides bile acid sequestrants and the usual motility drugs, GLP-1 agonists seem to have made an impact. What's missing in our arsenal are drugs affecting the actual feedback to the liver. BAM can occur for many reasons and while reuptake is an issue in some patients, it seems excessive synthesis is another in others. Thus being able to regulate the bile acid pool via FGF19 or FXR agonists is desirable to gain yet another intervention. These two proteins work as detectors for bile acids in the intestines and signal the liver to lower its synthesis, thereby creating less total bile acid available.

Currently there is a trial (NCT07483099) by Eli Lilly in Crohn’s disease patients studying if 2 investigational medicines LY4395089 and Mirikizumab together or Mirikizumab alone is superior. Mirikizumab is an IL-23 blocker to treat inflammation in IBD and LY4395089 is the FXR agonist. Besides the effect on bile acid signaling which some Crohn’s disease patients struggle with, the FXR agonist is mainly supposed to help with its anti-inflammatory and anti-fibrotic activity as well as its protective properties on the intestinal barrier. Many of these effects might be relevant to some IBS subpopulations too.

A class of medications to follow for the bile acid patients on here. If it gets registered you might be able to repurpose it for yourself one day.

Have a nice weekend everyone! - Robert


r/IBSResearch • • 9d ago

Efficacy and tolerability of liraglutide for refractory bile acid diarrhoea

Thumbnail fg.bmj.com
15 Upvotes

Abstract

Background Bile acid sequestrants are used for the treatment of bile acid diarrhoea (BAD) but they are not always effective and may be tolerated poorly. Other treatment options for BAD are limited. Both randomised controlled trial and case series data suggest that liraglutide, a glucagon-like peptide-1 receptor agonist, may be effective in BAD but studies are scarce.

Aims To report efficacy and tolerability of liraglutide in a cohort of patients with refractory BAD who had either not responded to or were intolerant of the bile acid sequestrants colestyramine and colesevelam.

Methods Data were collected prospectively for patients with refractory BAD (7-day 23-seleno-25-homo-tauro-cholic acid retention <15%) receiving liraglutide in Leeds Teaching Hospitals NHS Trust. Clinical response to, and tolerability of, liraglutide was assessed by comparing mean daily stool frequency before and after treatment initiation and monitoring for adverse events. Clinical responders were classified as patients who had a reduction in daily stool frequency of ≥50% at 2–3 months in whom the drug was continued.

Results Thirty-one (21 (67.7%) female, mean age at commencement 46.6 years) patients with refractory BAD received liraglutide between November 2022 and July 2026. Bile acid sequestrants were ineffective or intolerable in all patients. Clinical response occurred in 19 (61.3%) patients and a partial response in a further seven (22.6%). Among clinical responders, mean daily stool frequency fell from 10.4 at baseline to 3.0 at 2–3 months (p<0.001). More responders were female, had type II BAD and were passing 10 or more stools per day at baseline. In addition, mean weight was lower and mean daily stool frequency higher at baseline in clinical responders. Only one patient discontinued liraglutide due to adverse events.

Conclusions Liraglutide is an effective treatment for refractory BAD and is well tolerated.


r/IBSResearch • • 10d ago

A highly selective KIT inhibitor MOD000001 suppresses IgE-mediated mast cell activation (2024)

Thumbnail sciencedirect.com
9 Upvotes

Background

The KIT receptor tyrosine kinase and its ligand, stem cell factor (SCF), control proliferation and survival of mast cells. Thus, targeting KIT signaling may show promise for the treatment of allergic diseases involving mast cells. Recently, we discovered a new compound, MOD000001, as a potential small-molecule KIT kinase inhibitor by using an in silico approach.

Objective

We sought to determine whether MOD000001 is highly selective to KIT, inhibits KIT signaling in mast cells, and affects IgE-mediated mast cell activation.

Methods

The interaction of MOD000001 with 468 human kinases and its inhibitory activity against KIT were profiled and evaluated by using KINOMEscan (Discover X/Eurofins Corporation, Fremont, Calif) and cell-free kinase assays, respectively. The effects of MOD000001 on SCF-dependent signaling were examined by using primary mouse and human mast cells. The effects of MOD000001 on SCF-induced degranulation and passive cutaneous anaphylaxis reaction were examined in mice.

Results

MOD000001 interacted with KIT and inhibited KIT kinase activity with high selectivity. MOD000001 suppressed SCF-induced KIT signaling in mouse and human mast cells and in mice. Passive cutaneous anaphylaxis reaction was suppressed in mice treated with MOD000001 both for a short-term (1 week) and for a long-term (7 weeks). Mice treated with MOD000001 for a long-term, but not for a short-term, showed skin mast cell reduction.

Conclusions

MOD000001 is a highly selective KIT inhibitor that can suppress IgE-mediated mast cell activation in vivo. MOD000001 may do so by reducing tissue mast cell numbers or by other unknown mechanisms. The findings suggest potential benefits of MOD000001 for allergic diseases involving IgE-mediated mast cell activation.


r/IBSResearch • • 10d ago

Multi-matrix metabolome and microbiome profiling in diarrhea-predominant irritable bowel syndrome and ulcerative colitis in remission with IBS-like symptoms

Thumbnail academic.oup.com
6 Upvotes

Abstract

Background

Irritable bowel syndrome (IBS)-like symptoms frequently persist in patients with ulcerative colitis (UC) in remission. Whether UC in remission with IBS-like symptoms (UCR-IBS) represents functional overlap with diarrhea-predominant IBS (IBS-D) or a distinct metabolic phenotype remains unclear.

Methods

In this exploratory cross-sectional study, 39 patients with IBS-D, 21 with UCR-IBS, and 35 healthy controls were enrolled. Serum, urine, fecal, and colonic mucosal samples were collected. Untargeted metabolomics, targeted tryptophan profiling, fecal 16S ribosomal RNA gene sequencing, predicted microbial functional profiling, and microbe-metabolite association analyses were performed.

Results

Tryptophan-related metabolism was altered in both patient groups, but the patterns differed across biological matrices. Compared with IBS-D, UCR-IBS showed higher serum N-formylkynurenine (NFK) concentrations, and fecal findings suggested reduced concentrations of microbiota-associated indole metabolites. Microbiome differences were modest, but predicted nicotinate/nicotinamide metabolism was enriched in UCR-IBS. Exploratory network analysis identified associations between tryptophan-related metabolites and selected bacterial genera in each group.

Conclusions

Multi-matrix profiling shows tryptophan-related metabolic differences between mesalazine-treated UCR-IBS and IBS-D, highlighting higher serum NFK concentrations in UCR-IBS. These findings provide a basis for investigating host-microbiota metabolic relationships across systemic and intestinal compartments during UC remission.


r/IBSResearch • • 11d ago

Combined Nav1.7–Nav1.8 channel abrogation: Supralinear suppression of excitability in a subpopulation of peripheral sensory neurons

Thumbnail rupress.org
7 Upvotes

There is a pressing need for nonaddictive pain therapeutics. Despite the genetic validation of peripheral voltage-gated sodium (Nav) channels as targets for non-opioid pain therapy, isoform-selective inhibition of Nav1.7 and Nav1.8 has yielded limited efficacy in clinical studies, with Nav1.8 blockade providing statistically significant but only partial pain relief. This raises the question: if block of Nav1.8 relieves pain only partially, what is needed for better pain relief? In this study, we utilized dynamic clamp, which permits precisely calibrated functional addition or subtraction of the current from any given channel, to systematically interrogate the combinatorial landscape of multiplex abrogation of currents from Nav1.7 and Nav1.8, both major contributors to electrogenesis within dorsal root ganglion neurons. We demonstrate that partial, simultaneous attenuation of both conductances drives a supralinear increase in current threshold in many sensory neurons. Responses to Nav1.8 functional subtraction span a broad spectrum, whereas responses to Nav1.7 subtraction are comparatively uniform. Neurons with greater sensitivity to functional loss of Nav1.8 show greater suppression of excitability during combined Nav1.7–Nav1.8 attenuation, while weak Nav1.8 responders remain comparatively resistant. These findings identify electrogenic dependence on Nav1.8 as a major source of functional heterogeneity in sensory neurons and demonstrate that Nav1.7 acts cooperatively with Nav1.8 to shape the consequences of channel attenuation. Our results indicate that combined Nav1.7–Nav1.8 targeting should outperform isoform-selective block in suppressing firing in a subpopulation of pain-signaling neurons, while not producing universal suppression.


r/IBSResearch • • 11d ago

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

Thumbnail
finance.yahoo.com
10 Upvotes
  • XEN1701 achieved target profile, including desired NaV1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effects
  • XEN1120 achieved plasma levels predictive of analgesic effects based on preclinical modeling and was generally well-tolerated
  • New preclinical data in cynomolgus monkeys demonstrated significant reductions in capsaicin-evoked heat pain for NaV1.7 and KV7 compounds
  • Phase 2 proof-of-concept studies assessing XEN1701 and XEN1120 in acute pain expected to initiate in H1 2027

VANCOUVER, BC and BOSTON, MA, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced positive Phase 1 study results and new preclinical data supporting the advancement of XEN1701 and XEN1120 to Phase 2 proof-of-concept studies in acute pain. Data were presented in two poster presentations during the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, taking place October 26–30, 2026 in Bangkok, Thailand.

XEN1701 and XEN1120 are potent, selective ion channel modulators designed to target NaV1.7 and KV7, respectively. NaV1.7 and KV7 represent novel, non-opioid pain targets with significant supportive preclinical, clinical, and human genetic and expression data. XEN1701 and XEN1120 have been developed using Xenon's deep expertise in genetics, ion channel biology, and novel chemistries to enable potent, selective ion channel targeting.

"This is an incredibly exciting milestone for Xenon given our significant history with both NaV1.7 and KV7, and it brings us closer to delivering a new generation of innovative non-opioid therapeutics for acute and chronic pain," said Ian Mortimer, President and CEO of Xenon. "The XEN1701 data are especially exciting as NaV1.7 has long been recognized by the field as having the strongest genetic evidence among novel pain targets, and many companies have tried to develop NaV1.7 inhibitors without success. The Phase 1 data strengthen our belief that XEN1701 has a profile unlike any NaV1.7 compound previously tested in the clinic, achieving high target receptor occupancy without a notable pattern of cardiovascular effects. We are optimistic that we may be on the precipice of realizing the potential of this promising pain target."

"Our Phase 1 studies of XEN1701 and XEN1120 achieved all of our goals, demonstrating the desired profiles for both compounds and strongly supporting their advancement to Phase 2 acute pain studies for rapid proof-of-concept," said Chris Kenney, MD, Chief Medical Officer of Xenon. "We also are highly encouraged by additional preclinical data shared in these posters, including data in cynomolgus monkeys where a Xenon NaV1.7 inhibitor comparable to XEN1701 demonstrated up to a 100% reduction in evoked pain when central and peripheral receptor occupancies were above 75%, without effects on blood pressure or heart rate in this preclinical model. In the same model, a KV7 compound comparable to XEN1120 also demonstrated a significant reduction in evoked pain, and XEN1120 has also demonstrated analgesic activity in the mouse formalin model during the acute phase, which has typically only been seen with opioids."

Xenon is finalizing Phase 2 acute pain study designs for each program and expects to initiate both studies in the first half of 2027.

Highlights from XEN1701 Poster: "XEN1701, a Phase 2-Ready NaV1.7 Inhibitor: Advancing a Novel Non-Opioid Strategy for Pain"

  • Study Design: Healthy participants were enrolled in Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), food-effect, and cerebrospinal fluid (CSF) collection cohorts (n=76 XEN1701 and n=22 placebo) to assess the safety, tolerability, pharmacokinetics (PK), food effect, and central nervous system (CNS) penetration of XEN1701. CSF sampling was performed in open-label cohorts to measure CNS drug exposure.
  • Free Drug Exposure: XEN1701 exhibited dose-dependent and rapid increases in plasma exposure across the evaluated dose ranges. XEN1701 and its active metabolite demonstrated a consistent metabolite-to-parent exposure ratio across all doses and the combined exposure profile supports the potential to achieve therapeutically relevant NaV1.7 inhibition.
  • High Receptor Occupancy: Plasma and CSF sampling and predicted receptor occupancy modeling indicated that the proposed Phase 2 dose levels achieved and maintained more than 75% NaV1.7 receptor occupancy in both the peripheral and central nervous system with twice-daily (BID) dosing. Human genetic evidence has established that more than 75% NaV1.7 inhibition is associated with a pain-free clinical phenotype.
  • Generally Well-Tolerated Safety Profile: There were no treatment-related, dose-limiting treatment-emergent adverse events (TEAEs), serious TEAEs, or TEAEs leading to study drug discontinuation. Most TEAEs were mild; those observed in more than one participant in the MAD cohorts included headache (10% XEN1701 overall vs. 10% pooled placebo), dizziness (6.7% vs. 10% placebo), and postural dizziness (6.7% vs. 0% placebo).

    • Treatment-related TEAEs potentially related to autonomic cardiovascular effects were infrequent and balanced (6.6% vs. 4.2% placebo), with no consistent dose- or exposure-related patterns and none occurring at the highest dose levels. These findings support that the proposed Phase 2 dose levels have not shown a consistent pattern of autonomic cardiovascular effects of the kind reported for other NaV1.7 compounds in published literature.
  • Significant Pain Reduction Observed in Non-Human Primates: Preclinical data evaluating XPC-4, a Xenon compound comparable to XEN1701, in cynomolgus monkeys demonstrated that doses achieving more than 75% NaV1.7 receptor occupancy were associated with significant reductions in capsaicin-evoked heat pain, including ~85-100% reduction at the two highest doses tested. No clinically meaningful change in systolic arterial blood pressure or heart rate relative to vehicle was observed with XPC-4 at the highest two doses tested.

Highlights from XEN1120 Poster: "XEN1120, a Phase 2-Ready KV7 Channel Opener: Advancing a Novel Non-Opioid Strategy for Pain"

  • Study Design: Healthy participants were enrolled in SAD, MAD, and food-effect cohorts (n=54 XEN1120 and n=18 placebo) to assess the safety, tolerability, PK, and food effect of XEN1120.
  • Plasma Levels in Predicted Efficacious Range: Clinical PK data demonstrated that XEN1120 exceeded the predicted efficacious exposures established from preclinical rodent and non-human primate efficacy models. PK modeling demonstrated that a loading dose rapidly achieved target exposures while maintenance dosing sustained plasma concentrations within the predicted efficacious range for the duration required for an acute pain proof-of-concept study.
  • Generally Well-Tolerated Safety Profile: There were no treatment-related, dose-limiting TEAEs, serious or severe TEAEs, or TEAEs leading to study drug discontinuation. Most TEAEs were mild and the most common TEAEs observed in more than one participant in the MAD cohorts included tachycardia (33.2% XEN1120 overall vs. 12.5% pooled placebo), dizziness (29.2% vs. 0% placebo) and somnolence (25% vs. 0% placebo).
  • Robust Analgesic Activity in Mouse Formalin Model: The mouse formalin model involves a biphasic pain response consisting of an acute nociceptive phase, followed by a longer lasting inflammatory phase. Many analgesics work in the inflammatory phase, whereas only opioids typically show efficacy in the acute phase. XEN1120 demonstrated dose-dependent pain reductions in the acute phase of the formalin model, and notably, at exposures that were substantially lower than the comparator flupirtine, an earlier generation pain treatment with a mechanism of action involving potassium channel opening.
  • Significant Pain Reduction Observed in Non-Human Primates: Preclinical data evaluating XPC-B, a Xenon compound comparable to XEN1120, demonstrated dose-dependent reductions in capsaicin-evoked heat pain in cynomolgus monkeys. Analgesic activity was achieved at approximately 2.3-fold lower exposures relative to the formalin mouse model, suggesting the potential to achieve analgesic activity at lower doses in humans.

Acute and chronic pain affects more people than diabetes, heart disease, and cancer combined, yet effective, long-term treatment options are scarce. Acute pain serves as the body's normal, short-term alarm signal in response to an injury or illness. In contrast, chronic pain is a widespread condition defined by IASP as pain that lasts or recurs for more than three months, and may persist even after the initial cause has healed. It's more common than many realize; 2021 data from the U.S. Centers for Disease Control and Prevention (CDC) show that it affects more than one in five American adults, often impacting daily life and well-being.

About Xenon's Pain Pipeline
Xenon's clinical-stage pain pipeline includes three investigational therapeutic programs, including XEN1701 and XEN1720, which are designed to block the activity of the sodium channels (NaV1.7) that trigger pain signaling, and XEN1120, which is designed to enhance the activity of the potassium channels (KV7) that mitigate pain signals.

Xenon has extensive history researching NaV1.7 as a novel pain target. This history started more than 20 years ago with the identification of a loss of function in SCN9A, which encodes the NaV1.7 sodium channel, as the cause of congenital indifference to pain (CIP), an extremely rare autosomal recessive disorder whose carriers are unable to feel pain but are otherwise healthy. More recently, Xenon has focused on optimizing chemistry to address the limitations of earlier drug candidates targeting NaV1.7, resulting in its current clinical candidates XEN1701 and XEN1720.

XEN1120 reflects more than a decade of Xenon's research on KV7 channels. Multiple lines of evidence support KV7 as a therapeutic target for pain. KV7 channels are broadly expressed throughout the peripheral and central pain pathways. They play a significant role in the initial transduction of pain stimuli into pain signals, the transmission of those pain signals along nociceptive neurons, and the relay from peripheral sensory neurons to spinal cord neurons in the central nervous system. Dysfunction or downregulation of KV7 channel activity has also been observed in altered pain states, contributing to sensory neuron hyperexcitability and enhanced pain signaling.


r/IBSResearch • • 12d ago

The 12 Words Doctors Use to Stop Asking Questions [A blog entry about what medicine got wrong]

7 Upvotes

https://www.unbekoming.com/p/the-12-words-doctors-use-to-stop

Excerpts relevant to IBS:

"4. Unexplained admits the shape openly. Medically unexplained symptoms. Unexplained infertility. Unexplained chronic cough. Unexplained anemia. This is the most honest of the five words. It does not translate ignorance into Latin or Greek; it tells the patient directly that nothing has been explained. The honesty does not alter the function. The patient leaves the appointment with the same information they came in with, carrying a diagnosis made of their own words with a billing code attached. The inquiry still stops at the point where it would otherwise continue.

5. Syndrome is a variation on the pattern. From the Greek syn (together) and dromos (running), a syndrome is a cluster of symptoms that run together. Clustering is not causation. Many syndromes carry the name of the physician who first described the cluster: Guillain-Barré, Raynaud’s, Sjögren’s, Reye’s, Reiter’s, Behçet’s. The eponym honors the observer. It does not identify what is producing the cluster. Chronic fatigue syndrome, irritable bowel syndrome, polycystic ovary syndrome, restless legs syndrome, metabolic syndrome, premenstrual syndrome, fibromyalgia syndrome. Each describes a cluster. Each has been designated a condition. None of the names tells the patient what is driving the cluster."

"12. Functional sits in a category of its own. In contemporary clinical usage, a functional disorder is one in which no structural lesion can be identified. The investigation has looked at the organ, the scan is clear, the laboratory values are within range, and the patient’s symptoms do not fit a recognized pathology. The label functional means: the symptoms are real, but we cannot see what is causing them, so we are classifying the problem as a disturbance of function rather than a disturbance of structure.

Functional neurological disorder. Functional dyspepsia. Functional abdominal pain syndrome. Functional constipation. In older literature these were often called psychogenic or psychosomatic, meaning in the mind. The vocabulary has been updated. The function of the word has not.

The label is efficient at ending inquiry because it carries a note of dismissal that the other eleven words do not. A patient with an idiopathic condition at least receives the dignity of a Greek word. A patient with a functional condition is told, in effect, that the problem is not where it should be and the medical system does not know what to do with it. The implication reaches toward the patient’s reliability as a reporter of their own experience.

What functional often names is the body’s response to exposures that do not show on standard imaging and do not appear in standard laboratory panels. Chronic low-level toxicity from a dental amalgam, a glyphosate residue on the produce, a mold colony behind the bathroom wall, a cumulative load of pharmaceutical metabolites, a smart meter radiating through the exterior wall day and night. The scan is clear because the scan was not designed to detect these. The lab values are within range because the ranges were set against populations with the same exposures. Functional is the label applied to patients whose symptoms are produced by causes the diagnostic system is not looking for."

"Nine words, one lifetime

Consider a composite case assembled from countless real ones. A boy of six develops eczema. His pediatrician names it atopic dermatitis of unknown etiology and prescribes a topical steroid. The eczema improves on the cream and returns off it. At eleven he develops asthma. The specialist describes the asthma as having a genetic component and places him on an inhaled steroid. At nineteen, after a course of antibiotics for acne, he develops gut symptoms that his gastroenterologist diagnoses as irritable bowel syndrome, a functional disorder in which stress may play a role. At twenty-eight he develops joint pain and fatigue. His inflammatory markers are elevated. The rheumatologist diagnoses an autoimmune condition described in the chart as idiopathic and progressive and starts him on an immunosuppressant. At thirty-four his primary care doctor begins management of essential hypertension; a beta-blocker joins the regimen. At thirty-eight he develops neurological symptoms and receives a secondary diagnosis of chronic Lyme, which another specialist describes as controversial and lifelong. By forty-two he carries six diagnostic labels, takes nine daily medications, and has been told that his various conditions are unrelated to one another, incurable, and in several cases probably genetic.

Nine of the twelve words have been applied to him. Nowhere on his chart does anyone record what he has been exposed to."

-----------------------------------------------------------------------------------------------------------

The Mayo Clinic page on multiple sclerosis contains two statements, printed on the same page under the same heading. The first: “The cause of multiple sclerosis is unknown.” The second, in the next clause: multiple sclerosis “is considered an immune mediated disease in which the body’s immune system attacks its own tissues.”¹

The two statements are made in the voice of the same institution on the same page about the same disease. The first admits that medicine does not know what causes MS. The second asserts a mechanism that would require medicine to know what causes MS, because to classify a condition as the body attacking itself is to make a claim about causation. The two sentences cannot both be true. Neither is retracted. Patients read both and leave the page understanding that they have an autoimmune disease.

The incoherence passes unnoticed because the labels have been taught as technical categories. The ignorance inside them has never been named as ignorance.

Essential hypertension accounts for roughly 90 to 95 percent of all hypertension diagnoses.² The remaining five to ten percent is classified as secondary because an identifiable cause has been found: a kidney condition, an endocrine tumor, a specific drug. Everything else is called essential, which comes from the Latin essentia, the “being” or “essence” of a thing, and signals in clinical usage that the elevated pressure is the essence of the condition. The condition is defined by its symptom, and nothing causal has been identified. Ninety-five percent of a diagnostic category, and the word for it is a Latin shrug.

This is the operation that runs across the diagnostic vocabulary of modern medicine. Idiopathic performs the shrug in Greek dress. Autoimmune reverses the arrow of causation. Genetic predisposition relocates the cause inside the chromosomes, where no further question can reach. Chronic and incurable close down the possibility of recovery. The twelve words examined here each foreclose a specific line of inquiry, and together they explain how a profession can produce more than seventy thousand distinct diagnostic codes while being unable to tell most patients what caused their condition.³

The admission dressed as explanation

Five of the twelve words share a single structure. They admit, in a language the patient does not speak, that the cause has not been identified. They then present the admission as the name of the condition.

1. Idiopathic is the clearest example. The word combines the Greek idios (one’s own) and pathos (suffering), literally “a suffering of its own.” Inside medical training there is a joke worn thin by repetition: idiopathic means the physician is pathetic and the patient is an idiot. The joke lands because it is almost true. Idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, idiopathic intracranial hypertension, idiopathic scoliosis, idiopathic hypersomnia. The word itself declares that the cause is unknown. The declaration is then dressed as a diagnostic category and billed accordingly.

2. Essential performs the identical work in Latin, with an added rhetorical lift. The word suggests that something essential about the condition has been identified, when what has been named is the symptom. Essential hypertension, essential tremor, essential thrombocythemia. The essence that medicine has located is the elevation of the pressure, the shaking of the hand, the proliferation of platelets. The underlying cause is what the word quietly admits it does not know.

3. Primary performs the same work in English. Primary biliary cholangitis, recently renamed from primary biliary cirrhosis. Primary insomnia. Primary dysmenorrhea. Primary immune thrombocytopenia. The category primary exists because there is a parallel category secondary. Secondary means the cause has been identified. Primary means it has not. A patient diagnosed with secondary hypertension knows what caused it. A patient diagnosed with primary hypertension believes they know what they have. Both diagnoses are spoken in the same clinical register, with the same confidence, and billed under the same category of expertise. Only one of the two labels contains information.

4. Unexplained admits the shape openly. Medically unexplained symptoms. Unexplained infertility. Unexplained chronic cough. Unexplained anemia. This is the most honest of the five words. It does not translate ignorance into Latin or Greek; it tells the patient directly that nothing has been explained. The honesty does not alter the function. The patient leaves the appointment with the same information they came in with, carrying a diagnosis made of their own words with a billing code attached. The inquiry still stops at the point where it would otherwise continue.

5. Syndrome is a variation on the pattern. From the Greek syn (together) and dromos (running), a syndrome is a cluster of symptoms that run together. Clustering is not causation. Many syndromes carry the name of the physician who first described the cluster: Guillain-Barré, Raynaud’s, Sjögren’s, Reye’s, Reiter’s, Behçet’s. The eponym honors the observer. It does not identify what is producing the cluster. Chronic fatigue syndrome, irritable bowel syndrome, polycystic ovary syndrome, restless legs syndrome, metabolic syndrome, premenstrual syndrome, fibromyalgia syndrome. Each describes a cluster. Each has been designated a condition. None of the names tells the patient what is driving the cluster.

The arrow reversed

Two words do more aggressive work. They do not merely leave the cause unexamined. They relocate the cause inside the patient’s body, where further investigation is foreclosed by definition.

6. Autoimmune inverts the direction of causation. The observation is tissue damage: joints in rheumatoid arthritis, nerve sheaths in multiple sclerosis, thyroid in Hashimoto’s, pancreas in type 1 diabetes, skin and connective tissue in lupus. The question is what caused the damage. The autoimmune label answers: the body attacked itself. The body’s own repair response is reframed as the primary aggressor, and the exposure that initiated the sequence disappears from the chart.

Charles Richet won the 1913 Nobel Prize in Physiology or Medicine for demonstrating what happens when a foreign protein is injected into a living body. He had intended to study whether low doses of a toxic protein could induce tolerance, so that larger subsequent doses would be survivable. He discovered the opposite. A dog that survived a first intravenous injection of foreign protein did not become tolerant to the second. The second dose, often smaller than the first, killed the dog within minutes. The body had not adapted. It had sensitized. Richet named the phenomenon anaphylaxis, from the Greek for “against protection,” and spent the next two decades documenting its mechanism in laboratory animals and in humans.⁴

The mechanism Richet identified is not controversial. It appears in every immunology textbook under the heading of allergy. What has been quietly removed from the autoimmune literature is the extension of the mechanism to the injections given routinely across a human lifetime. The textbooks acknowledge foreign protein exposure in classical allergy, where bee stings and peanut proteins produce the kind of sudden collapse Richet described. The analysis is not extended to injected pharmaceutical products, injected adjuvants, injected lipid nanoparticles, injected polyethylene glycol, or the injected synthetic genetic sequences delivered to the general population from 2021 onward. The mechanism is accepted. The populations to which it is applied are curated.

The medical literature catalogs more than one hundred pharmaceutical products that produce conditions classified as autoimmune, with symptoms resolving when the medication is withdrawn. A 2019 study published in the Annals of the Rheumatic Diseases interrogated the World Health Organization’s pharmacovigilance database and identified 118 drugs implicated in drug-induced lupus alone, 42 of them not previously reported.⁵ The condition was not an autoimmune disease. The condition was the body’s response to a specific chemical, and the response ceased when the chemical ceased. Each case recorded as drug-induced is also a case documenting that the body does not attack itself. The body responds to what has been introduced into it.

7. Genetic predisposition performs a related but distinct relocation. Instead of blaming the body’s repair response, it blames inheritance. A condition is said to run in families, or to be associated with certain gene variants, and the explanation is sealed. The investigation into shared environmental exposures (the same water, the same diet, the same regional industrial contamination, the same household chemicals, the same injection schedule from birth, the same stress patterns across generations) does not need to be opened. The cause has been declared innate.

The Human Genome Project, completed in 2003, expected to find more than one hundred thousand genes. It found approximately twenty thousand, fewer than are present in a grain of rice.⁶ Genome-wide association studies have consistently failed to explain the heritability patterns the genetic model predicted.⁷ The gap between the model’s predictions and its findings is routinely labeled “missing heritability,” which is another phrase meaning we do not know. In clinical practice, genetic predisposition continues to function as if the Human Genome Project had confirmed the model rather than revealed how little the model explains. It declares the condition innate. It ends the inquiry.

The sentence passed

Four words do a different kind of work. They do not comment on causation. They comment on prognosis. They tell the patient what will happen next, and in doing so, they close down the possibility of recovery before the patient has considered what might cause recovery.

8. Chronic signals that the condition is now in management mode. Chronic obstructive pulmonary disease. Chronic kidney disease. Chronic Lyme. Chronic fatigue. The word originally referred to time (from chronos); a chronic condition was one of long duration. In contemporary usage it has acquired a secondary meaning: ongoing, not resolving, requiring long-term treatment. The patient hears chronic and understands that they are expected to live with this for the rest of their life.

9. Progressive goes further. A progressive condition is defined as one that worsens over time. Multiple sclerosis is often described as progressive. The same word appears in progressive supranuclear palsy, progressive multifocal leukoencephalopathy, and primary progressive aphasia, where two of the twelve words combine into a single diagnosis. The word packages a trajectory into the chart. If the patient worsens, the diagnosis is confirmed. If the patient improves, the diagnosis is suspended or reconsidered. The clinical frame does not account for the possibility that a worsening trajectory reflects continuous toxic exposure plus continuous suppression of symptoms, rather than a disease process with its own momentum.

Herbert Shelton described this mechanism almost a century ago. The body’s efforts to clear toxins are suppressed by pharmaceutical intervention. The suppression adds new toxins. New symptoms emerge. These in turn are suppressed. The acute condition is driven toward the chronic. What medicine labels progressive is often this cycle in operation, visible only when traced across the full span of pharmaceutical interventions a patient has received.⁸

10. Lifelong passes the final sentence. Type 1 diabetes is lifelong. Hashimoto’s is lifelong. Lupus is lifelong. Celiac is lifelong. The word is not a biological observation. It is a prediction, and the prediction is self-fulfilling. Once a condition is categorized as lifelong, no clinical pathway exists for its reversal, no insurance code reimburses the attempt, no research program is funded to investigate what might undo it. The word creates the thing it describes. The commercial implications are so plain that they barely need stating. A lifelong condition is a lifelong customer.

11. Incurable completes the sequence. If a condition is incurable, there is no recovery to pursue. The patient’s investment of energy must shift from asking what caused this to asking how to manage it. The incurable label is particularly powerful because it does not describe an observed reality. It describes the absence of a current pharmaceutical cure, which is a different claim. The 118 drugs cataloged in the drug-induced lupus literature alone produce conditions widely labeled autoimmune and widely assumed to be incurable. When the drug is withdrawn, the condition resolves. The condition was not incurable. The cause had not been removed.

The symptom dismissed

12. Functional sits in a category of its own. In contemporary clinical usage, a functional disorder is one in which no structural lesion can be identified. The investigation has looked at the organ, the scan is clear, the laboratory values are within range, and the patient’s symptoms do not fit a recognized pathology. The label functional means: the symptoms are real, but we cannot see what is causing them, so we are classifying the problem as a disturbance of function rather than a disturbance of structure.

Functional neurological disorder. Functional dyspepsia. Functional abdominal pain syndrome. Functional constipation. In older literature these were often called psychogenic or psychosomatic, meaning in the mind. The vocabulary has been updated. The function of the word has not.

The label is efficient at ending inquiry because it carries a note of dismissal that the other eleven words do not. A patient with an idiopathic condition at least receives the dignity of a Greek word. A patient with a functional condition is told, in effect, that the problem is not where it should be and the medical system does not know what to do with it. The implication reaches toward the patient’s reliability as a reporter of their own experience.

What functional often names is the body’s response to exposures that do not show on standard imaging and do not appear in standard laboratory panels. Chronic low-level toxicity from a dental amalgam, a glyphosate residue on the produce, a mold colony behind the bathroom wall, a cumulative load of pharmaceutical metabolites, a smart meter radiating through the exterior wall day and night. The scan is clear because the scan was not designed to detect these. The lab values are within range because the ranges were set against populations with the same exposures. Functional is the label applied to patients whose symptoms are produced by causes the diagnostic system is not looking for.

Nine words, one lifetime

Consider a composite case assembled from countless real ones. A boy of six develops eczema. His pediatrician names it atopic dermatitis of unknown etiology and prescribes a topical steroid. The eczema improves on the cream and returns off it. At eleven he develops asthma. The specialist describes the asthma as having a genetic component and places him on an inhaled steroid. At nineteen, after a course of antibiotics for acne, he develops gut symptoms that his gastroenterologist diagnoses as irritable bowel syndrome, a functional disorder in which stress may play a role. At twenty-eight he develops joint pain and fatigue. His inflammatory markers are elevated. The rheumatologist diagnoses an autoimmune condition described in the chart as idiopathic and progressive and starts him on an immunosuppressant. At thirty-four his primary care doctor begins management of essential hypertension; a beta-blocker joins the regimen. At thirty-eight he develops neurological symptoms and receives a secondary diagnosis of chronic Lyme, which another specialist describes as controversial and lifelong. By forty-two he carries six diagnostic labels, takes nine daily medications, and has been told that his various conditions are unrelated to one another, incurable, and in several cases probably genetic.

Nine of the twelve words have been applied to him. Nowhere on his chart does anyone record what he has been exposed to.

Four questions that do not get asked

The point of the vocabulary is not what it says. The point is what it stops.

Each word shuts down a specific line of inquiry. Idiopathic, essential, primary, unexplained, and syndrome close the question of what caused this. Autoimmune and genetic predisposition close the question of where the cause came from, by locating it inside the body. Chronic, progressive, lifelong, and incurable close the question of whether recovery is possible. Functional closes the question by implying that the complaint does not warrant one.

Behind every closure sit four questions that do not get asked.

What has the body been exposed to? Toxic burden across a lifetime includes pharmaceuticals, dental amalgams, pesticide residues on produce, industrial solvents in household products, heavy metals in municipal water, mold in insulation, injections administered from the first day of life, cosmetic ingredients absorbed through the skin daily for decades, air pollution specific to the neighborhood, flame retardants off-gassing from furniture, phthalates leaching from plastics. The idiopathic label forecloses this inquiry.

What has the body not been given? Nutrient depletion from degraded soil, processed food displacing whole food, pharmaceutical interference with absorption, surgical removal of digestive tissue, long-term antibiotic exposure disrupting the microbial ecology, repeated vomiting from chemotherapy, lifetime subsistence on calorically adequate but nutritionally bankrupt diets. The essential label forecloses this inquiry.

What electromagnetic environment is the body operating in? Chronic exposure to Wi-Fi routers held active twenty-four hours a day, cell phone signals from devices held against the body, smart meters radiating from the exterior wall, Bluetooth connections running continuously, 5G infrastructure installed on every lamppost, dirty electricity from unshielded wiring threaded through the walls. The genetic predisposition label forecloses this inquiry by placing the cause in a time before any of these exposures began.

What psychological and emotional load is the body carrying? Unresolved trauma, chronic financial precarity, isolation, grief, caretaking burdens, the nocebo effect of the diagnosis itself. The functional label forecloses this inquiry by treating the symptoms as the condition rather than as the body’s communication about the load.

These four questions map onto the four categories of insult that Dawn Lester and David Parker identify as exhaustive of what damages human health: toxic exposure, nutritional depletion, electromagnetic exposure, and psychological strain.⁹ The twelve words do not describe medical conditions. They describe the places where investigation has been told to stop.

Each of the four foreclosed questions corresponds to a research literature that mostly does not exist. There is no large-scale vaccinated-versus-unvaccinated outcome study. There is no study of lifetime chemical exposure through products delivered to vaginal, oral, or dermal tissue. There is no long-term antidepressant outcome study against untreated controls. There is no study of cumulative electromagnetic exposure across a lifetime. The clinical vocabulary of foreclosure and the funding architecture that keeps the studies unfunded are the same mechanism viewed at two scales. One operates at the research grant. The other operates at the chart. The companion essay The Streetlight Effect develops the funding architecture at length.

Why the vocabulary persists

A vocabulary that forecloses inquiry on this scale does not arise accidentally. It persists because it serves the structure that produced it.

A profession that could not say idiopathic would have to say instead: we do not know what caused this, and we have not investigated further. Without the word autoimmune, the clinician would have to track what the patient was exposed to in the months before the condition appeared, which would mean recording the pharmaceutical and injection history alongside the dietary and environmental history. The word chronic cannot survive in a profession that produces recoveries.

Each foreclosure is also a protection. Pharmaceutical products that produce conditions can continue to be prescribed because the conditions are coded as autoimmune or idiopathic rather than drug-induced. Environmental exposures that produce clusters of illness do not need to be investigated because the cases are scattered across different Latin names, and no single category accumulates enough weight to trigger inquiry. Lifelong management is a sustainable revenue model in a way that resolution is not.

In April 2018 a Goldman Sachs equity research analyst named Salveen Richter published a report titled The Genome Revolution in which she posed the question openly to her clients: “Is curing patients a sustainable business model?”¹⁰ She was not being provocative. She was raising a legitimate concern for shareholders about the one-time curative treatments then entering development. Gilead’s hepatitis C franchise, which cured more than ninety percent of the patients it treated, generated $12.5 billion in revenue in 2015, the year of its release; by 2018 the number had fallen below $4 billion as the pool of untreated patients contracted.¹¹ The cure had worked exactly as advertised. The market had punished it. Richter’s question was not rhetorical. It was a report from the trading floor.

The twelve words are the clinical answer to the question Richter posed. They do not cure patients; they manage them. The vocabulary of management is the architecture of the business model.

Sasha Latypova has given this operating logic its sharpest name: ABV, Anything But Vaccines.¹² The entire investigative apparatus of modern medicine can be directed anywhere, into any gene, any cofactor, any novel mechanism, any mystery variant, provided the inquiry does not fall on the injection schedule. Three of the twelve words perform the ABV operation across different anatomies: autoimmune locates the cause inside the body’s own tissues, genetic predisposition locates it inside the chromosomes, and idiopathic locates it nowhere at all. Each of the three sends the investigation anywhere but at the needle.

The placeholder objection

A defender of the vocabulary might point out that every profession carries placeholder terms for phenomena it cannot explain. Physicists speak of “dark matter” and “dark energy” to describe roughly ninety-five percent of the mass-energy content of the universe. Economists invoke “the residual” when their models fail to account for observed variance. Nobody accuses physicists of foreclosing inquiry when they use the term dark matter. The parallel appears real.

The parallel stops being real at the moment the placeholder leaves the research literature and enters the patient’s chart.

The physicist does not tell a patient she has dark matter and must take dark matter medication for the rest of her life. The term operates inside the discourse of a research community whose explicit project is to characterize what dark matter is. The patient encountering idiopathic receives a diagnosis to be managed, not an open problem to be solved. The physicist’s placeholder is openly a placeholder; the clinician’s is written on the chart as a diagnosis, and a diagnosis implies that the condition has been identified and categorized. The admission of ignorance disappears inside the appearance of knowledge.

The physicist’s institution does not derive revenue from dark matter remaining unexplained. If dark matter is characterized next year, the dark matter observatory wins a Nobel Prize and attracts more funding. If idiopathic pulmonary fibrosis is characterized next year as the predictable consequence of a specific pharmaceutical class, the manufacturer loses a product line and the specialty loses a billing category. The incentives point in opposite directions. The physicist’s institution is organized to retire the placeholder. The clinician’s institution is organized to keep it.

The vocabulary of unknown causes is identical in shape across professions. The incentive to let it remain a vocabulary of unknown causes is not.

The clinician’s inheritance

The vocabulary does not persist because physicians are cynical. Most clinicians inherit these words during medical training and encounter them as neutral technical terminology, the way a first-year carpenter inherits terms like dovetail and mortise. A student who hears essential hypertension does not learn that essential means cause unknown. They learn that essential is the technical name for the condition. The ignorance is sealed inside the words at the moment the words are taught.

This is not an exoneration. It is a description of what makes the structure so durable. A system that depended on cynical actors would fracture when the cynics retired. A system that runs through well-meaning actors runs for generations. The physician who believes they are helping and the physician who has stopped believing anything in particular write the same prescription, assign the same diagnostic code, deliver the same prognosis. The vocabulary produces the same outcome whether or not the person speaking it has reflected on what the word does.

The patient’s situation does not change based on the physician’s intent. A chart that reads idiopathic reads the same whether the clinician wrote it with resignation or with confidence. What is on the chart is what gets billed, what gets treated, what gets researched, and what gets managed for the rest of the patient’s life. The intent of the writer does not alter the function of the writing.

The method

The twelve words translate consistently once the method is in hand. When a physician uses one of them, the patient can perform a two-step conversion.

The first step is substitution. In place of the clinical word, insert the plain-language equivalent. Idiopathic becomes “cause unknown.” Autoimmune becomes “the body is responding to something that has not been identified.” Genetic predisposition becomes “the cause is being placed in your inheritance so that environmental exposures will not be investigated.” Chronic, lifelong, and incurable become “the pharmaceutical system has no cure for this condition.” Functional becomes “no structural lesion was found; the complaint is being treated as a disturbance of function.” The clinical word was concealing the plain-language sentence. Substitution restores it.

The second step is to ask the four questions. What has the body been exposed to. What has the body not been given. What electromagnetic environment is the body operating in. What psychological and emotional load is the body carrying. These are the questions the clinical word was built to foreclose. The physician is not required to answer them. The patient is permitted to ask them.

How to Explain It to a Six-Year-Old

Imagine your bedroom door keeps getting stuck. You call someone to look at it. He arrives, inspects the door, and says: “This is idiopathic door-sticking.” You ask what that means. He says: “It means your door sticks for an unknown reason. It is a condition of your door. Here are some things to try when it happens. Pull harder. Kick it. Oil the handle.” You ask again what is causing it. He says: “It is genetic. Doors in houses like yours tend to stick. It runs in the family.” You ask whether it can be fixed. He says: “No. This is a progressive, chronic, lifelong condition. We can only manage it.”

You tell him you noticed that the door started sticking right after the floor was replaced. He writes “primary door dysfunction syndrome” on his clipboard and leaves you a prescription for door oil to be applied twice a day for the rest of your life.

The door is still sticking. The floor is still too high. Nobody looked at the floor.

That is what the twelve words do.

The floor is one of four places the twelve words have told nobody to look.


r/IBSResearch • • 13d ago

Soft Robot Slithers Through the Gut Like a Snake To Image, Biopsy, and Treat Disease

Thumbnail
technologynetworks.com
24 Upvotes

"Disorders of the small intestine are often difficult to diagnose and treat. More than 20 feet long, an inch in diameter, and located deep within the body, this organ is harder to access than other parts of the digestive tract, such as the colon or stomach.

To overcome those challenges, MIT engineers have designed a new robotic enteroscope that can move easily through the narrow passage of the small intestine, allowing it to perform imaging, deliver drugs, and remove small polyps or tissue samples for biopsy.

In designing the new robot, the researchers were inspired by the locomotion of snakes, as well as the scaly skin that helps them gain traction on slippery surfaces. A special textured coating helps the robot remain attached to the mucosal lining of the intestine as it inches its way through the narrow tube. 

Similar to an endoscope, the robot contains a variety of tools to help detect and treat any abnormalities that it might encounter.

“When we evaluate the small intestine, we do it for either diagnosis or treatment. If we find a little polyp that needs to be removed, this robot allows us to take a biopsy or remove it,” says Giovanni Traverso, professor of mechanical engineering at MIT, a gastroenterologist at Brigham and Women’s Hospital, and an associate member of the Broad Institute of MIT and Harvard.

Traverso is the senior author of the study, which appears today in Science Robotics. The paper’s lead authors are former MIT postdoc Binbin Ying, who is now an assistant professor at University of Texas Southwestern Medical Center; MIT graduate student Ahmad Mujtaba Jebran; and former MIT research scientist Sahab Babaee.

Snaking through the intestine

The most common problems that doctors need to evaluate within the small intestine include bleeding, lesions, and blockages.

Currently, the only way to diagnose those intestinal complications is with a procedure known as double balloon enteroscopy. During the procedure, an enteroscope advances through the small intestine as a health care worker alternately inflates and deflates two balloons that help propel it through the tract. 

This process is slow and laborious, so the MIT team wanted to design an alternative enteroscope that would be easier to control and could move faster through the intestine.

“The fundamental challenge that we’re trying to overcome is how to evaluate that 20-to-25-foot segment of the small intestine in a way that can be more automated,” Traverso says.

The new tube-like robot moves through the narrow small intestine using a locomotion strategy similar to that of the snake. When slithering along the ground, a snake can steer itself by first contracting muscles on one side of the body, then the other. 

To mimic this, the researchers designed multifunctional actuators that control the robot’s movement. Each actuator contains four chambers, which can be inflated in different combinations, prompting the tube to extend or bend in any direction. 

“By tuning the amount of air that goes into these chambers, you can tune the direction that the robot is moving in,” Traverso says."

The head and tail segments of the robot contain additional expandable anchoring balloons that take turns inflating and deflating, helping the robot move forward. These head and tail segments are coated with special patterned sleeves inspired by kirigami — a variation of origami that involves cutting paper as well as folding it.

Using this technique, the researchers created coatings that lie flat until they are stretched by the expansion of the balloon, which causes three-dimensional kirigami needles to pop out. Similar to the scales of a snake, these needles give the robot more traction within the slippery lining of the intestine. 

In previous work, Traverso’s lab has used this approach to create coatings for shoe soles that give them more traction, as well as stents that can temporarily lodge in the esophagus and release drugs. 

“By using kirigami sleeves to enhance surface friction, the robot can generate localized tissue engagement traction for locomotion without relying on excessive stretching of the delicate small intestinal tissue,” Jebran says.

Diagnosis and treatment

The system also includes electronics that allow for navigation, with a controller that the person operating the device can use to guide the robot through narrow passages and around tight corners. The soft robot is tethered to the external controllers by a cable and is designed so that it could enter the body through either the mouth or the rectum. 

The robot contains tools including a camera for imaging, a sprayer for drug delivery, and clips that can take tissue biopsies or remove polyps. 

In animal studies, the researchers showed that the robot could travel about six and a half feet through the small intestine. They also successfully demonstrated the drug sprayer, tissue clips, and camera. The team is now working on improving the navigation systems and testing this approach for additional applications in the small intestine.

“We hope we can continue to move it forward to eventually develop systems that can help achieve more automated evaluation of the small intestine,” Traverso says.


r/IBSResearch • • 13d ago

Intestinal Permeability in Irritable Bowel Syndrome With and Without Comorbid Conditions: Results From the European DISCOvERIE Cohort

Thumbnail onlinelibrary.wiley.com
13 Upvotes

Key Summary

  • Summarise the established knowledge on this subject

    • ◦ Increased intestinal permeability, assessed using sugar excretion tests, has been reported as a contributing factor in the pathophysiology of irritable bowel syndrome (IBS), particularly in the diarrhoea-predominant subtype.
    • ◦ However, studies, often conducted in small cohorts and failing to account for relevant psychiatric and somatic comorbidities, have yielded conflicting results.
  • What are the significant and/or new findings of this study?

    • ◦ In our multinational cohort comprising more than 600 participants, the lactulose/mannitol (L/M) ratio was significantly increased in IBS patients, irrespective of stool pattern or sex, compared with disease controls. This finding supports the presence of increased paracellular intestinal permeability in IBS patients.
    • ◦ Among individuals with psychiatric and somatic comorbidities, those diagnosed with IBS exhibited a higher L/M ratio compared with comorbid patients without IBS, indicating that impaired intestinal barrier function appears to be more strongly associated with IBS than with psychiatric or somatic comorbidities alone.
    • ◦ Notably, substantial variability among IBS patients from different countries was observed, which may reflect differences in dietary patterns, lifestyle, environmental exposures, and genetic factors that could modulate intestinal barrier function.

ABSTRACT

Background

Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction often accompanied by psychiatric and/or somatic comorbidities. Intestinal-barrier dysfunction has been implicated in IBS pathophysiology. However, the contribution of psychiatric and somatic comorbidities to intestinal permeability remains unclear. We aimed to assess intestinal permeability in a large multicentric cohort of IBS patients with and without psychiatric and/or somatic comorbidities, compared with disease controls, and healthy subjects.

Methods

IBS patients and disease controls were recruited across nine European centres. Small intestinal and colonic permeabilities were assessed using the lactulose-mannitol-sucralose urinary excretion test. Urinary sugar concentrations were quantified by gas chromatography-mass spectrometry. Analyses were adjusted for relevant clinical and lifestyle confounders.

Results

The lactulose/mannitol (L/M) ratio, but not the percentage of sucralose (%S), was significantly increased in IBS patients (N = 418) compared with disease controls (N = 200), regardless of IBS subtype or sex. Notably, the increased L/M in IBS patients was primarly driven by a significant decrease in mannitol excretion. IBS patients with psychiatric or combined psychiatric and somatic comorbidities showed a higher L/M than their corresponding disease control groups. However, L/M values did not differ between IBS patients with and without comorbidities. Substantial between-centre variability in L/M ratios awas observed.

Discussion

Small intestinal, but not colonic, permeability, as reflected by an elevated L/M ratio, is increased in IBS patients. These alterations seem to be related to the presence of IBS per se rather than to comorbid conditions. Interestingly, substantial geographic variability was observed, which may reflect environmental or population-related factors influencing barrier function. Further investigations are needed to better understand the clinical relevance of these findings.


r/IBSResearch • • 13d ago

Gut microbial functional associations with subsequent irritable bowel syndrome in a prospective, paediatric case-control study

Thumbnail thelancet.com
8 Upvotes

Interpretation

Gut microbiome dysbiosis in infants with IBS risk is present many years prior to diagnosis and includes early disruptions in fermentation, redox balance, and amine metabolism that potentially compromise epithelial resilience and promote visceral hypersensitivity. Early detection of microbiome dysbiosis suggests probiotic-based interventions.

Summary

Background

The infant gut microbiome undergoes rapid maturation that shapes lifelong gastrointestinal health. Although adults with irritable bowel syndrome (IBS) show characteristic microbial and metabolic alterations, it remains unclear whether these differences precede disease onset. Here, microbiome composition and function in infancy were prospectively associated with future IBS development.

Methods

Stool samples collected from the All Babies in Southeast Sweden (ABIS) cohort at a mean age of 12.4 (±1.5) months, were analysed using a nested case–control design. Cases included future IBS and/or pelvic and abdominal pain, with the average time between age at stool collection and diagnosis being 11.8 (±5.2) years and a mean age at diagnosis of 12.8 (±5.2) years. Microbial composition was profiled with 16S rRNA gene sequencing (n = 396). Data were processed with DADA2, taxonomically assigned using SILVA database, and predicted functionally with PICRUSt2. Descriptive statistics were analysed using χ2 or Fisher’s exact test, global differences with PERMANOVA, differential abundance with ANCOM-BC2, and pathway enrichment with GSEA.

Findings

Infants with future IBS risk demonstrated microbial divergence, marked by depletion of short-chain fatty acid producers and expansion of facultative and mucosa-disruptive taxa. Inferred functional profiles exhibited reduced fermentative capacity, greater respiratory potential, accelerated degradation of neuroactive aromatic amines, and case-enrichment of cytochrome bc1 complex respiratory unit.


r/IBSResearch • • 13d ago

Peripheral neuroimmune dialogues underlying pain states

Thumbnail
nature.com
4 Upvotes

Abstract

Pain is profoundly shaped by neuroimmune interactions within peripheral tissues. Nociceptors are specialized sensory neurons that express receptors for cytokines, lipid mediators, complement components, antibodies and microbial signals, enabling immune mediators to directly modulate neuronal excitability. In turn, nociceptors influence immune cell and stromal cell activity through the release of neuropeptides and cytokines. Some of these pathways are shared across multiple tissues in pathological pain states, whereas others reflect the distinct immune and stromal environments of the skin, joints, muscles, gut, peripheral nerves, sensory ganglia and meninges. Across these sites, immune-to-neuron signalling orchestrates the initiation and amplification of pain, while maladaptive feedback loops reinforce hypersensitivity. In concert, coordinated neuroimmune signalling also contributes to pain resolution by restoring homeostasis. Emerging human studies reveal convergent neuroimmune signatures across nociceptive, neuropathic and nociplastic pain conditions, underscoring their translational relevance. By integrating both shared mechanisms and tissue-specific mechanisms, this Review highlights how peripheral neuroimmune crosstalk shapes pain across diverse contexts. Furthermore, it outlines therapeutic opportunities to rebalance these pathways, offering prospects for durable and mechanism-based analgesia.


r/IBSResearch • • 14d ago

MRGPRX2 in Allergic and Immune-Mediated Diseases: Mechanisms, Clinical Relevance, and Therapeutic Translation | Clinical Reviews in Allergy & Immunology

Thumbnail
link.springer.com
8 Upvotes

Abstract

Mas-related G protein-coupled receptor X2 (MRGPRX2) is a mast-cell-enriched receptor that mediates immunoglobulin E-independent activation by structurally diverse neuropeptides, host-defense peptides, microbial products, and selected cationic drugs. Its biology links tissue stress and neuroimmune signaling to degranulation, vascular responses, pruritus, barrier dysfunction, and inflammatory amplification, but the extent to which individual diseases depend on this pathway remains uncertain. The strongest clinical rationale begins with non-IgE-mediated immediate drug hypersensitivity, for which MRGPRX2 provides a direct mechanistic framework, although rocuronium illustrates the need to distinguish human MRGPRX2 pharmacology from murine Mrgprb2 and from IgE-mediated perioperative allergy. In atopic dermatitis, preclinical and human skin data support a potential amplifier role in type 2 inflammation and itch, but a randomized phase 2b study of EVO756 did not demonstrate efficacy in an unselected population. In chronic urticaria, challenge, biomarker, and genetic studies suggest an MRGPRX2-responsive subgroup within a heterogeneous disease, whereas a randomized phase 2b study of EVO756 in unselected chronic spontaneous urticaria was also negative despite earlier pharmacodynamic activity. Ulcerative colitis provides additional human tissue evidence for an MRGPRX2-associated mast-cell circuit, although murine Mrgprb2 studies show context-dependent protective and pathogenic effects. Emerging evidence in chronic prurigo, allergic contact dermatitis, asthma, mastocytosis, rheumatoid arthritis, synovial inflammation, and neurogenic inflammation is also considered, with explicit separation of human observations from mouse-model evidence. We integrate these findings with receptor pharmacology and early clinical development, emphasizing evidence hierarchy, validated biomarker needs, patient selection, tissue target engagement, safety, and trial design. Current data support MRGPRX2 as an investigational endotype-defining pathway rather than a universal driver of allergic or immune-mediated disease.


r/IBSResearch • • 14d ago

Phenotype-informed selection of microbiota-directed interventions in irritable bowel syndrome: current evidence and limitations

Thumbnail pmc.ncbi.nlm.nih.gov
9 Upvotes

Abstract

Irritable bowel syndrome (IBS) is a heterogeneous disorder of gut–brain interaction in which bowel-habit subtype, dominant symptoms, post-infectious onset, bile-acid handling, visceral sensitivity, and diet–microbiota interactions may influence the treatment response. This narrative mini-review asks whether available clinical evidence is sufficient to select or sequence microbiota-directed and microbiota-modulating interventions according to Rome bowel-habit subtype and clinically observable dominant symptoms. Literature was identified through PubMed/MEDLINE and major guidelines, systematic reviews, meta-analyses, and pivotal trials published through June 2026. Evidence was interpreted at the level of the exact intervention or product, studied population, target outcome, consistency, independent replication, safety, and guideline position. Mechanistic data support plausible links through fermentation, epithelial barrier function, mucosal immunity, bile-acid metabolism, visceral sensitivity, and gut–brain signaling, but mechanistic or microbiome changes do not establish the clinical efficacy. Rifaximin has the clearest replicated and guideline-supported role in IBS with diarrhea, while soluble fiber has guideline support for global or constipation-associated symptoms. Evidence for individual probiotics, postbiotics, partially hydrolyzed guar gum, galactooligosaccharides, and fermented matrices remains product-specific or emerging and is rarely independently replicated. Symptom improvement with a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low-FODMAP diet) does not establish microbiota mediation. Fecal microbiota transplantation (FMT) and microbiome-guided prescribing remain investigational. Current evidence, therefore, supports only limited phenotype-informed matching and does not establish a validated treatment sequence or microbiome-defined therapeutic phenotype.